Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | NAT1 | P18440 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | MAX | P61244 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8618544 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL7768284 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8535410 | 0.92 | PTGS2 (0.85) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8535412 | 0.92 | PTGS2 (0.85) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL10519512 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8536872 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL8536869 | 0.87 | PTGS2 (0.76) | PTGS2PTGS1NAT1MEN1NPC1 | |
| SCHEMBL3667216 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 | |
| SCHEMBL8962138 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 | |
| SCHEMBL3667218 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1NAT1GAACISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | claimed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | claimed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | claimed |
| JP-2290862-A | — | — | None | — | — | JP | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5691367-A | ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5143928-A | Inhibitors of cyclooxygenase and lipoxygenase | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0449216-A1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
| JP-H02290862-A | ARYL-SUBSTITUTED RHODANINE DERIVATIVE | ELI LILLY & CO | 1990-11-30 | — | — | JP | disclosed |
| EP-0391644-A2 | Aryl-substituted rhodanine derivatives | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0211670-B1 | DI-T-BUTYLPHENOL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0211670-A2 | Di-t-butylphenol compounds | ELI LILLY AND COMPANY (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PTGS2 4802/4885PTGS1 4600/4885NAT1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.